Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | BRAF | P15056 | 7/20 | 0.36 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.36 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699853 | 1.00 | MKNK1 (0.59) | MKNK1EGFRBRAFTNNI3KPIP4K2A | |
| SCHEMBL16700519 | 0.92 | MKNK1 (0.60) | MKNK1EGFRPIP4K2C | |
| SCHEMBL16700518 | 0.92 | MKNK1 (0.60) | MKNK1EGFRPIP4K2C | |
| SCHEMBL16700232 | 0.89 | MKNK1 (0.60) | MKNK1EGFRTP53 | |
| SCHEMBL16705866 | 0.89 | MKNK1 (0.60) | MKNK1EGFRTP53 | |
| SCHEMBL16700236 | 0.89 | MKNK1 (0.60) | MKNK1EGFRTP53 | |
| SCHEMBL16701015 | 0.88 | MKNK1 (0.61) | MKNK1EGFR | |
| SCHEMBL16700045 | 0.87 | MKNK1 (0.58) | MKNK1EGFR | |
| SCHEMBL16700689 | 0.86 | MKNK1 (0.69) | MKNK1EGFR | |
| SCHEMBL16700687 | 0.86 | MKNK1 (0.69) | MKNK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | claimed |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | DPYD, VEGFA, FLT1 | MKNK1 2315/4885EGFR 1218/4885BRAF 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.